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APP-BP1 mediates APP-induced apoptosis and DNA 
synthesis and is increased in Alzheimer’s disease brain
 
Yuzhi Chen, Wenyun Liu, Donna L. McPhie, Linda Hassinger, and Rachael L. Neve
 
Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478
 
PP-BP1, ﬁrst identiﬁed as an amyloid precursor
protein (APP) binding protein, is the regulatory
subunit of the activating enzyme for the small
ubiquitin-like protein NEDD8. We have shown that APP-
BP1 drives the S- to M-phase transition in dividing cells,
and causes apoptosis in neurons (Chen, Y., D.L. McPhie,
J. Hirschberg, and R.L. Neve. 2000. 
 
J
 
. 
 
Biol
 
. 
 
Chem
 
. 275:
8929–8935). We now demonstrate that APP-BP1 binds to
the COOH-terminal 31 amino acids of APP (C31) and
colocalizes with APP in a lipid-enriched fraction called lipid
rafts. We show that coexpression of a peptide representing
the domain of APP-BP1 that binds to APP, abolishes the
ability of overexpressed APP or the V642I mutant of APP to
A
 
cause neuronal apoptosis and DNA synthesis. A domi-
nant negative mutant of the NEDD8 conjugating enzyme
hUbc12, which participates in the ubiquitin-like pathway
initiated by APP-BP1, blocks neuronal apoptosis caused by
APP, APP(V642I), C31, or overexpression of APP-BP1.
Neurons overexpressing APP or APP(V642I) show increased
APP-BP1 protein levels in lipid rafts. A similar increase in
APP-BP1 in lipid rafts is observed in the Alzheimer’s disease
brain hippocampus, but not in less-affected areas of Alz-
heimer’s disease brain. This translocation of APP-BP1 to
lipid rafts is accompanied by a change in the subcellular
localization of the ubiquitin-like protein NEDD8, which is
activated by APP-BP1.
 
Introduction
 
The mechanism by which neurons die in Alzheimer’s disease
(AD) remains to be defined. However, the participation of
the amyloid precursor protein (APP) in at least some aspects
of the etiology of the disease is suggested by the facts that
mutations in this gene can cause familial AD (FAD) and
that APP is overexpressed in Down’s syndrome, a disorder
that culminates in AD-like neurodegeneration. Therefore,
it is useful to understand the normal function of APP, as
impairments of its function may contribute to AD neuropa-
thology. For example, cleavage of APP by 
 
 
 
- and 
 
 
 
-secretases
not only generates the pathological amyloid 
 
 
 
 (A
 
 
 
) peptide
but also releases an intracellular fragment (APP intracellular
 
cleavage domain [AICD]) that can cause apoptosis in
neuroglioma cells (Kinoshita et al., 2002).
A subset of total APP is found on the cell surface in neurons
(Jung et al., 1996), suggesting that a percentage of APP may
function as a cell surface receptor, transducing signals from
the ECM to the interior of the cell. Consistent with this
notion, a number of proteins have been shown to interact
with the COOH-terminal, intracellular portion of APP,
among them the growth cone G protein G
 
o
 
 (Nishimoto et
al., 1993), the presumptive adaptor proteins Fe65 and X11
(for review see Russo et al., 1998), UV-DDB (Watanabe et
al., 1999), histone acetyltransferase Tip60 (Cao and Sudhof,
2001), and Jun NH
 
2
 
-terminal kinase interaction protein 1
(Scheinfeld et al., 2002).
Previously, we identified an additional binding protein for
the intracellular domain of APP, APP-BP1 (Chow et al.,
1996). We showed that APP-BP1 is a cell cycle protein that
acts in vivo as one half of the bipartite activating enzyme for
the ubiquitin-like protein NEDD8 (Chen et al., 2000).
Expression of APP-BP1 in dividing cells drives the cell cycle
through the S-M checkpoint; this function is mediated by
the NEDD8 conjugation (neddylation) pathway. In primary
neurons, overexpression of APP-BP1 causes apoptosis; this
apoptosis can be blocked by inhibition of neddylation
(Chen et al., 2000).
Here, we dissect the nature of the interaction of APP-BP1
 
with APP, to determine whether disruptions in this interaction
may play a role in AD neurodegeneration. We show that
APP-BP1 binds to the COOH-terminal 31 aa of APP
(C31), and that both proteins are located in lipid rafts. We
demonstrate that APP, as well as APP-BP1, overexpression
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causes DNA synthesis and apoptosis in neurons, and that in-
teraction of APP with APP-BP1 is required for activation of
these pathways. Inhibition of neddylation blocks neuronal
apoptosis caused not only by overexpression of APP-BP1
and APP but also by the V642I mutation of APP and by
C31. Neurons expressing APP or APP(V642I) show an in-
crease in APP-BP1 levels in lipid rafts, which is also observed
in AD hippocampus. The increase in APP-BP1 is accompa-
nied by a change in the subcellular localization of the ubiq-
uitin-like protein NEDD8, which is activated by APP-BP1.
 
Results and discussion
 
APP-BP1 interacts with the COOH-terminal 
31 aa of APP
 
APP-BP1 was first identified as a protein that interacts with
the intracellular domain of APP (Chow et al., 1996). We
performed coimmunoprecipitations to identify with greater
specificity the region of APP to which APP-BP1 binds. Pri-
mary rat cortical cells were infected with HSV vectors ex-
pressing APP-BP1 and myc epitope-tagged C31. Myc-C31
was immunoprecipitated from the neuronal cell lysates with
9E10, an antibody specific for the myc epitope. As shown in
Fig. 1 A, APP-BP1 coprecipitated with myc-C31 in the
presence but not in the absence of the primary antibody, in-
dicating that APP-BP1 binds to the C31 of APP. C31,
which is generated by intracellular caspase cleavage, causes
apoptosis in neuronal cells (Lu et al., 2000; Galvan et al.,
2002) and is responsible for the apoptosis caused by FAD
mutants of APP (McPhie et al., 2001). The binding of APP-
BP1 to C31 suggests involvement of APP-BP1 in neuronal
apoptosis caused by this fragment.
 
APP-BP1 and APP colocalize to lipid rafts
 
APP has been reported to localize to the detergent-insoluble
and lipid-enriched low density fraction (lipid rafts). To de-
termine whether APP-BP1 colocalizes with APP in lipid
rafts, we fractionated rat brain homogenates (Chen and
Norkin, 1999) and used immunoblots to detect the frac-
tions in which APP and APP-BP1 were enriched. As shown
in Fig. 1 B, both APP and APP-BP1 are greatly enriched in
fractions 5 and 6, which contain lipid rafts. Our data show-
ing colocalization of APP with APP-BP1 in lipid rafts sug-
gest that not only APP processing but also APP signaling
mediated by APP-BP1 may occur in the lipid rafts.
 
HSV-APP–induced apoptosis and DNA synthesis are 
blocked by coexpression of a peptide that competes 
with APP-BP1 for binding to APP
 
We have shown previously that either overexpression of
wild-type (WT) APP or expression of FAD mutants of APP
in neurons induces apoptosis and DNA synthesis (McPhie
et al., 2001, 2003). To determine whether APP-BP1 inter-
action with APP is involved in either of these pathways, we
used HSV vectors to coexpress in neurons a peptide repre-
senting the domain of APP-BP1 that binds to APP (Chow et
al., 1996; Chen et al., 2000), together with WT APP or
APP(V642I). Fig. 2 (A and B) shows that expression of this
peptide, APP-BP1(145-251), blocks neuronal apoptosis and
DNA synthesis caused by WT APP or APP(V642I), suggest-
ing that interaction of APP with APP-BP1 is required for the
activation of these pathways.
Consistent with our previous data (McPhie et al., 2001,
2003), neuronal apoptosis and DNA synthesis caused by
overexpression of WT APP is intermediate between that seen
in control and that caused by APP(V642I) (Fig. 2, A and B).
This is not surprising because we have reported that expres-
sion of FAD APP mutants in neurons results in greater accu-
mulation of the 
 
 
 
-secretase cleavage product of APP (C99)
than does overexpression of WT APP in neurons (McPhie et
al., 1997). C99 is a preferred substrate for production of both
AICD (Passer et al., 2000) and C31 (Lu et al., 2000), and has
been shown to be increased in AD brain (Holsinger et al.,
2002; Yang et al., 2003). C99 is also a substrate for the pro-
duction of the A
 
 
 
 fragment, which has been shown to be
toxic to neurons in culture. However, our prior data (McPhie
et al., 2001) show that neuronal apoptosis caused by FAD
mutants of APP is independent of A
 
 
 
 production by these
mutants indicating that A
 
 
 
 caused neurotoxicity is likely to
involve a separate pathway from that mediated by APP-BP1.
Fig. 2 C illustrates the increase in DNA synthesis caused by
APP(V642I), showing incorporation of BrdU into the DNA
of neurons infected with HSV-APP(V642I). To confirm that
the increase in DNA synthesis caused by APP(V642I) and
blocked by APP-BP1(145-251) occurs specifically in neurons,
we stained the neurons with a monoclonal anti-NeuN anti-
body, specific for neuronal nuclei, together with a polyclonal
anti-BrdU antibody. As shown in Fig. 2 C (b), cells that are
Figure 1. APP-BP1 interacts with APP-C31 in lipid rafts. (A) Primary 
neurons were infected with HSV vectors expressing APP-BP1 and 
myc-C31. Myc-C31 was precipitated from the cell lysate with the 
anti-myc antibody 9E10. The blot was probed with the anti–APP-BP1 
antibody BP339. The plus and minus signs indicate presence or 
absence of the primary antibody, respectively, in the immunopre-
cipitation. APP-BP1 coprecipitated with myc-C31, but when no 
primary antibody was present, APP-BP1 was not coprecipitated. 
The lane labeled “whole cell” represents 4% of the lysate used for 
immunoprecipitation. (B) Adult rat brain was fractionated to isolate 
lipid rafts; the ganglioside GM1, detected by HRP-conjugated cholera 
toxin, was used as a marker for the lipid rafts. APP-BP1 was detected 
with the rabbit antibody BP339, and APP with the rabbit antibody 
369. Both APP-BP1 and APP were enriched in the lipid raft low 
density fractions (lanes 5 and 6). The image was captured with the 
imaging system from Imaging Research, Inc. using the MCID software.T
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positively immunolabeled with anti-BrdU are colabeled with
the antibody to NeuN, verifying their identity as neurons.
The fact that APP-BP1 apparently mediates APP-induced
neuronal DNA synthesis is not unexpected, given our previ-
ous finding that APP-BP1 is necessary for cell cycle progres-
sion (Chen et al., 2000). However, in neurons this entry into
the cell cycle causes apoptosis rather than cell cycle progres-
sion. The induction of DNA synthesis in neurons by overex-
pression of WT APP or of APP(V642I) is consistent with the
data reported by Yang et al. (2001), who demonstrated that a
significant number of hippocampal pyramidal and basal fore-
brain neurons in AD brain compared with control brain have
undergone full or partial DNA replication.
 
APP-induced neuronal apoptosis is antagonized 
by disruption of the neddylation pathway that 
is initiated by APP-BP1
 
Overexpression of APP-BP1 in primary neurons causes
apoptosis by a pathway that also involves hUbc12, the
NEDD8-conjugating enzyme in the neddylation pathway
initiated by APP-BP1. Coexpression of a dominant negative
 
Figure 2.
 
WT APP- and APP(V642I)-induced neuronal apoptosis 
and DNA synthesis are inhibited by coexpression of a peptide that 
competes with APP-BP1 for binding to APP or by blockade of the 
APP-BP1 neddylation pathway.
 
 (A) Apoptosis induced by overex-
pression of HSV-APP or HSV-APP(V642I) is inhibited by coinfection 
with an HSV vector expressing HA-tagged APP-BP1(145-251), which 
competes with APP-BP1 for binding to APP. A two-tailed 
 
t
 
 test 
revealed significant differences between APP versus APP 
 
 
 
 APP-
BP1(145-251) (P 
 
  
 
0.001) and between APP(V642I) versus 
APP(V642I) 
 
  
 
APP-BP1(145-251) (P 
 
  
 
0.001). APP-BP1(145-251) 
versus LacZ is not significant. (B) Neuronal DNA synthesis induced 
by HSV-APP or HSV-APP(V642I) is inhibited by coinfection with an 
HSV vector expressing HA-tagged APP-BP1(145-251), which 
competes with APP-BP1 for binding to APP. A two-tailed 
 
t
 
 test 
revealed significant differences between APP versus APP 
 
 
 
 APP-
BP1(145-251) and between APP(V642I) versus APP(V642I) 
 
  
 
APP-
BP1(145-251) (P 
 
  
 
0.001). APP-BP1(145-251) versus LacZ is not 
significant. (C) DNA synthesis induced by APP(V642I) and blocked 
by APP-BP1 (145-251) is primarily neuronal. Rat cortical cultures 
were infected with HSV vectors and labeled with BrdU. Cells were 
fixed and stained with rabbit polyclonal anti-BrdU plus Alexa 488–
conjugated secondary (green) and the neuron-specific mouse 
monoclonal anti-NeuN plus Cy5-conjugated secondary (red). 
Double-labeled cells represent neurons undergoing DNA synthesis. 
The four panels represent neuronal cultures infected with the following 
vectors: (a) HSV-HA-APP-BP1(145-251); and (b) HSV-APP(V642I). 
Double-labeled neurons were present, showing APP(V642I)-induced 
DNA synthesis in neurons; (c) HSV-HA-APP-BP1(145-251) plus 
HSV-APP(V642I); the peptide was able to block DNA synthesis 
induced by APP(V642I); and (d) Mock. Bar, 10 
 
 
 
m. (D) A dominant 
negative mutant (C111S) of hUbc12, the NEDD8-conjugating enzyme 
in the neddylation pathway initiated by APP-BP1, blocks apoptosis 
induced by APP-BP1, APP, APP(V642I), or GST-C31. A two-tailed 
 
t
 
 test revealed the following significant differences: APP-BP1 versus 
APP-BP1 
 
  
 
C111S (P 
 
  
 
0.001), APP versus APP 
 
  
 
C111S (P 
 
  
 
0.01), 
APP(V642I) versus APP(V642I) 
 
  
 
C111S (P 
 
  
 
0.01), and GST-C31 
versus GST-C31 
 
 
 
 C111S (P 
 
  
 
0.001). (E) A dominant negative 
mutant (C111S) of hUbc12 does not block apoptosis induced by 
treatment of neurons with 10 
 
 
 
M camptothecin (Camp). A two-tailed 
 
t
 
 test revealed the following significant differences: Camp-18 h 
versus control and Camp-4 h versus control (P 
 
  
 
0001). Camp-18 h 
versus Camp
 
 
 
C111S and Camp-2 h versus control were not 
significant. All error bars represent SEM.T
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in Fig. 3 (A and B; not depicted). These data suggest that
WT APP and APP(V642I) cause the activation of cell cycle
machinery and consequent apoptosis in neurons by increas-
ing APP-BP1 levels specifically in lipid rafts.
 
APP-BP1 protein levels are increased in 
Triton X-100–insoluble compartments of 
hippocampal cells in postmortem AD brain
 
Our observation that overexpression of WT APP and
APP(V642I) in neurons causes an increase in APP-BP1 pro-
tein in the Triton X-100–insoluble fraction suggests that
APP-BP1 protein might also be increased in AD brain in the
same fraction. Therefore, we performed immunoblot analy-
ses of hippocampal tissue samples from postmortem AD and
control brains (Fig. 3 C). Equal amounts of Triton X-100–
insoluble proteins from each sample were analyzed with the
anti–APP-BP1 antibody BP339. Densitometric analysis of
the blots showed that levels of APP-BP1 were significantly
increased in AD hippocampus relative to control hippocam-
pus (Fig. 3 C, b).
Immunofluorescent staining of Triton X-100–treated hip-
pocampal tissue sections with BP339 (Fig. 3 D) showed in-
creased APP-BP1 in pyramidal cells in the hippocampus,
supporting the immunoblot results. Brodmann areas 9 and
17, less pathologically affected in AD, were also analyzed by
immunoblot, and did not show elevated levels of APP-BP1
over those in the same regions of control brain (Fig. 3 E).
We did not observe increased APP-BP1 protein levels in the
hippocampus of Parkinson’s disease brains relative to con-
trols (Fig. 3 F).
 
NEDD8 is translocated to the cytoplasm in hippocampal 
neurons in AD brain and in cultured neurons 
overexpressing APP-BP1
 
NEDD8 is a small ubiquitin-like protein that is activated by
APP-BP1/hUba3 and covalently conjugated to target proteins
such as the cullins. During most phases of the cell cycle,
NEDD8 is located predominantly in the nucleus, but as mi-
tosis begins, it moves to a predominantly cytoplasmic location
(Kurz et al., 2002). Given that WT APP and APP(V642I)
cause neuronal DNA synthesis that is mediated by APP-BP1,
we predicted that NEDD8 may show a shift from a neuronal
to a cytoplasmic localization in affected regions of AD brain.
Indeed, we did observe such a shift (Fig. 4 A). We immuno-
stained the hippocampus in five cases of AD and five match-
ing controls with rabbit anti-NEDD8. In four out of five AD
cases examined, NEDD8 was located primarily in the cyto-
plasm in hippocampal neurons. In contrast, in four out of five
control cases, NEDD8 was located primarily in the nucleus in
hippocampal neurons. Although the postmortem interval av-
erage for the control cases was slightly longer than that for the
AD cases (average of 20 
 
 
 
 1.28 h vs. 15 
 
 
 
 1.96 h), there was
no correlation between postmortem interval and NEDD8 lo-
calization in the cases that were examined. These data rein-
force the notion that neurons in AD brain may be entering
the cell cycle, and support the observation by Yang et al.
(2001) that a significant number of hippocampal pyramidal
and basal forebrain neurons in AD brain compared with con-
trol brain have undergone full or partial DNA replication.
mutant (C111S) of hUbc12 with APP-BP1 prevents APP-
BP1–mediated neuronal apoptosis (Chen et al., 2000). We
asked whether hUbc12(C111S) also blocks APP-induced
apoptosis in neurons. As shown in Fig. 2 D, coexpression of
hUbc12(C111S) with HSV-APP or with HSV-APP(V642I)
reduces apoptosis induced by these viral recombinants
nearly to control levels.
We suggested previously (McPhie et al., 2001) that APP
C31 is responsible for the apoptosis caused by FAD mutants
of APP. Therefore, we asked whether apoptosis caused by
C31 is mediated by the neddylation pathway. Neurons in
culture were infected with HSV vectors expressing GST-
tagged C31 alone or in combination with hUbc12(C111S).
The results (Fig. 2 D) confirm that C31 directly causes neu-
ronal apoptosis, and that this apoptosis is inhibited by dom-
inant negative hUbc12. Thus, activation of the neddylation
pathway mediates neuronal apoptosis caused by APP-BP1,
WT APP, APP(V642I), and C31.
To ascertain whether the dominant negative mutant of
hUbc12 has a general effect on apoptotic pathways, we
tested the effect of expression of hUbc12 dominant negative
mutant on neurons treated with camptothecin, a topo-
isomerase inhibitor that activates the G1 to S transition in
neurons and causes neuronal apoptosis (Park et al., 1997).
Camptothecin induced a significant increase in DNA frag-
mentation in cortical cells; this effect peaked at 18 h (Fig. 2
E). This increase in DNA fragmentation was not prevented
by coinfection with HSV expressing the dominant negative
mutant of hUbc12 (Fig. 2 E). These data suggest either that
camptothecin acts in a distinct apoptotic pathway or that its
effects on apoptosis are distal to the effect of APP-BP1 in the
same pathway.
The data above support the idea that APP-BP1 interaction
with APP signals cells to divide via the neddylation pathway,
causing differentiated neurons to die.
 
Expression of FAD APP(V642I) in neurons causes 
increased expression of APP-BP1 in the 
Triton X-100–insoluble fraction
 
We have demonstrated that overexpression of APP-BP1
causes apoptosis in neurons. These data suggest that WT or
FAD APPs may initiate the apoptotic pathway at least partly
by increasing the level of APP-BP1 in neurons. To test this
hypothesis, levels of APP-BP1 were assayed in lysates of neu-
rons that had been infected with HSV-APP or HSV-
APP(V642I) (Fig. 3 A). When primary cortical cultures were
infected with these recombinant viruses, the level of the en-
dogenous APP-BP1 in the Triton X-100–insoluble/SDS-
soluble fraction (lipid rafts) was increased many fold over
basal levels. Expression of WT APP in neurons caused an in-
termediate increase in APP-BP1 levels in lipid rafts, consis-
tent with our previous observation that overexpression of
APP in neurons causes a level of DNA synthesis and apopto-
sis intermediate between that caused by APP(V642I) and
that seen in control cultures. Camptothecin did not cause an
increase of APP-BP1 in lipid rafts (Fig. 3 B); in fact, it
caused a decrease, suggesting again that it acts by a different
pathway from that activated by APP. No differences in total
cellular APP-BP1 levels were detected in the samples shownT
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The data that APP-BP1 protein is increased in lipid rafts in
hippocampal neurons in AD, and that NEDD8 is translo-
cated to the cytoplasm in this same population of neurons,
suggest that elevation of APP-BP1 in lipid rafts may cause the
shift in NEDD8 subcellular location. We tested this hypoth-
esis by infecting primary neurons in culture with HSV-myc-
APP-BP1. This manipulation increases levels of APP-BP1 in
lipid rafts as well as elsewhere in the cell (unpublished data).
4 h after infection, the cells were fixed and stained with anti-
myc antibody 9E10 and an anti-NEDD8 antibody, after
which they were counterstained with propidium iodide to
demarcate the nucleus. Confocal microscopic analysis (Fig. 4
B) revealed that endogenous NEDD8 levels in the nucleus
were significantly decreased in HSV-myc-APP-BP1–infected
neurons relative to uninfected neurons. In contrast (Fig. 4
C), camptothecin treatment caused an increase rather than a
decrease in NEDD8 levels in the nucleus.
 
Conclusions
 
In summary, APP-BP1 interacts with APP within the
COOH-terminal 31 aa of APP, and the two proteins coexist
in lipid rafts. Induction of apoptosis or DNA synthesis in
neurons by overexpression of wild type APP or APP(V642I)
depends on the interaction of APP with APP-BP1 and is
blocked by inhibition of neddylation. The levels of endoge-
nous APP-BP1 protein in lipid rafts are both increased by
APP or APP(V642I) overexpression in primary neuronal cul-
tures and also increased in AD hippocampus. This increase in
APP-BP1 levels in lipid rafts is associated with the transloca-
tion of NEDD8 from the nucleus to the cytoplasm both in
AD hippocampal neurons and in primary neuronal cultures.
Our data suggest that neuronal apoptosis induced by over-
expression of APP is mediated by its interaction with APP-
BP1 in lipid rafts, which activates the neddylation pathway
and induces cell cycle entry. It has been reported previously
 
Figure 3.
 
APP-BP1 levels in lipid rafts are increased in primary 
neurons overexpressing APP or APP(V642I)
 
 
 
and in AD hippocampus.
 
 
(A) Triton X-100–insoluble fractions from HSV-infected primary 
neurons were analyzed by immunoblot expression for endogenous 
APP-BP1 protein expression. APP-BP1 was up-regulated in the 
HSV-APP– and HSV-APP(V642I)–infected neurons, but not in the 
HSV-LacZ–infected neurons. The experiment was repeated three 
times. The density of APP-BP1 for each sample was first normalized 
to actin, and then calculated as fold of LacZ (LacZ 
 
  
 
1). Error bars 
represent SEM for three independent experiments. (B) Triton X-100–
insoluble fractions from primary neurons treated with 10 
 
 
 
M 
camptothecin (camp) or vehicle (DMSO) were analyzed by immuno-
blot expression for endogenous APP-BP1 protein expression. APP-BP1 
levels in the lipid rafts were down-regulated by camptothecin. The 
density of APP-BP1 for each sample was normalized to actin. Error 
bars represent SEM for two independent experiments. (C) Frozen 
postmortem human brain tissue was homogenized, and protein from 
the Triton X-100–insoluble fraction was analyzed by immunoblotting 
with the anti–APP-BP1 antibody BP339 (a). Densitometric analysis of 
the immunoblot data (b), in which the APP-BP1 signal was normalized 
to the actin signal, revealed a significant difference between APP-BP1 
levels in control (Con) and AD hippocampus, by two-tailed 
 
t
 
 test 
(P 
 
  
 
0.026). Error bars represent SEM after APP-BP1 levels were 
normalized to actin. (D) PFA-fixed human hippocampal tissue 
sections were immunostained in the presence of Triton X-100 with 
the anti–APP-BP1 antibody BP339 plus Alexa 488–conjugated 
secondary antibody. APP-BP1 immunofluorescence was visualized 
by confocal microscopy, using the same settings for each case. CA2 
pyramidal cells are shown. Bar, 20 
 
 
 
m. (E) APP-BP1 protein levels 
in the Triton X-100–insoluble fraction from Brodmann areas 9 and 
17 are not significantly different in AD brain from their levels in 
control brain. For the analysis of APP-BP1 in the hippocampus and 
area 17, nine AD and nine control cases were used. For the area 9 
analysis, eight AD and eight control cases were used. The APP-BP1 
signal was normalized to that for actin. Error bars represent SEM after 
APP-BP1 levels were normalized to actin. (F) APP-BP1 is expressed 
at higher levels in AD hippocampus than in the Parkinson’s disease 
hippocampus. Equal amounts of protein from the Triton X-100–
insoluble fraction, two cases from each category, were analyzed. 
The APP-BP1 signal was normalized to that for actin. Error bars 
represent SD after APP-BP1 levels were normalized to actin.T
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that the AICD, to which APP-BP1 binds, causes neuronal
apoptosis via its effects on transcription (Kinoshita et al.,
2002). One clue to the connection between APP-BP1 and the
transcriptional pathway activated by the AICD is suggested
by the finding that activation of NF-
 
 
 
B inhibits the transcrip-
tional activity of AICD (Zhao and Lee, 2003). We have
shown that the neddylation pathway inhibits NF-
 
 
 
B activa-
tion (Chen et al., 2003). One may infer from these findings
that activation of the neddylation pathway by APP-BP1 an-
tagonizes the inhibition of the transcriptional activity of
 
AICD by NF-
 
 
 
B, resulting in increased AICD transcriptional
activity.
 
Materials and methods
 
Primary rat cortical culture and HSV infection
 
For apoptosis and DNA synthesis assays, primary cortical cultures from
E17/18 rat embryos were plated at a density of 3.5 
 
 
 
 10
 
5
 
 viable cells per
35-mm well containing poly-
 
D
 
-lysine–coated glass coverslips. 4–5 d after
plating, neurons were infected with the appropriate viruses at a multiplicity
of infection of one per virus. In experiments in which two different viruses
were coexpressed, HSV-LacZ was added to the conditions involving ex-
pression of single viruses, to equalize the amount of virus in all conditions.
 
Plasmid construction
 
All plasmid constructs were made in the pHSVPrpUC vector or in the
pcDNA3 vector using standard techniques, and were verified by sequence
analysis. The APP-BP1 and dominant negative hUbc12 HSV vectors have
been described previously (Chen et al., 2000), as have been the APP-695,
APP(V642I), and myc-C31 HSV vectors (McPhie et al., 1997, 2001).
 
Antibodies and immunoblots
 
The polyclonal antibody 369, raised against amino acids 645–694 of hu-
man APP
 
695
 
, was a gift from S. Gandy (Thomas Jefferson University, Phila-
 
Table I. 
 
Summary of human brain materials used
Brain type Case PMI Age Sex Pathology grade
 
h
 
Control 3803 25 81 M mild AD changes
4072 21 69 F mild AD changes
4106 19 74 M mild AD changes
4354 15 68 F
4367 26 75 F
4481 20 65 M
4646 22 68 F
4722 26 60 M mild AD changes
4571 24 71 M
4585 22 59 M mild AD changes
4595 17 65 M
4298 22 75 F
4320 15 62 M
 
a
 
4343  5 76 M mild AD changes
 
a
 
4393 18 70 F
 
a
 
4596 25 49 M
 
a
 
4480 18 57 M
 
a
 
Alzheimer’s 
disease 4282 13 65 M 4
4286 20 69 F 2 genetic
4319 23 84 M 4
 
a
 
4358 18 73 F 2
 
a
 
4370 25 74 F 2
4152 7 63 M 3
4559 14 61 F 3
4495  5 67 M 2
4639 24 67 M 1
4233 14 73 F 3
 
a
 
4336 16 76 F 3
 
a
 
4342  3 73 F 3
4420 13 68 M 2
 
a
 
Parkinson’s 
disease 4078 12 72 F
4934 17 68 M
 
 
a
 
Cases used for immunocytochemistry.
Figure 4. NEDD8 shows a shift from the nucleus to the cytoplasm 
in AD hippocampal neurons and in cultured neurons overexpressing 
APP-BP1. (A) PFA-fixed human postmortem brain sections were 
immunostained with rabbit anti-NEDD8. Confocal microscopic 
images of NEDD8 immunofluorescence in CA2 pyramidal cells and 
granule cells were visualized. Bar, 20  m. (B) Primary neuronal 
cultures were infected with HSV-myc-APP-BP1. 4 h later, cells were 
fixed with 4% PFA and immunostained with mouse anti-myc antibody 
9E10 (1:400; visualized with Alexa Fluor 488 goat anti–mouse), and 
10  g/ml rabbit anti-NEDD8 (visualized with Cy5 goat anti–rabbit). 
Cell nuclei were counterstained with 50 ug/ml propidium iodide 
(Sigma-Aldrich) for 5 min. The density of NEDD8 in the nuclei of 
HSV-myc-APP-BP1-infected versus uninfected neurons on the same 
slide was quantified with confocal software (Leica); the difference 
was shown to be significant (P   0.0001). (C) Primary neuronal 
cultures were treated with 10  M camptothecin (camp) for 4 or 18 h, 
or with vehicle (DMSO) for 18 h. Either 4 or 18 h of camptothecin 
treatment caused an increase in the density of NEDD8 in the nuclei 
of neurons versus the vehicle control (P   0.001). All error bars 
represent SEM.T
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delphia, PA). The anti-myc antibody 9E10 and the anti-APP antibody
22C11 were both obtained from CHEMICON International, Inc. or Upstate
Biotechnology. The anti–APP-BP1 antibody BP339 has been described
previously (Chen et al., 2000). The other antibodies used include: rabbit
polyclonal anti-BrdU (Megabase Research Products); mouse monoclonal
anti-NeuN (CHEMICON International, Inc.); Cy5-conjugated secondary
(Jackson ImmunoResearch Laboratories); 10 
 
 
 
g/ml of rabbit anti-NEDD8
(Qbiogene or Zymed Laboratories); and myc antibody 9E10 (1:400;
CHEMICON International, Inc.). HRP-conjugated cholera toxin, propidium
iodide and (S)-(
 
 
 
)-camptothecin all were obtained from Sigma-Aldrich.
Immunoblots were performed as described previously (Chen et al., 2000).
 
Coimmunoprecipitation
 
Rat primary neurons were infected with HSV-APP-BP1 and HSV myc-C31
for 4 h. Coimmunoprecipitation was performed as described previously
(McPhie et al., 2003). The lysate was incubated with the anti-myc antibody
9E10 overnight and then with protein G for 2 h. The immune complex was
resolved by SDS-PAGE, and subjected to immunoblot analysis with anti–
APP-BP1 antibody BP339.
 
Apoptosis and DNA synthesis assays
 
For apoptosis assays, primary cortical cultures were infected with the ap-
propriate viruses at an multiplicity of infection of one, and 14 h later, the
cells were fixed for 20 min with 4% PFA and stained with bisbenzimide as
described previously (McPhie et al., 2001). 10 random fields of 100–200
cells were analyzed for each condition. The number of cells with con-
densed nuclei relative to the total number of cells per field was calculated
and expressed as a percentage. All experiments were repeated three to four
times. Both the DNA synthesis assays and the statistical analyses have
been described in detail in Chen et al. (2003).
 
Immunocytochemistry with postmortem human brain sections 
and with ethanol-fixed primary neurons
 
40-
 
 
 
m-thick postmortem brain tissues fixed in PFA (Table I; Harvard Brain
Tissue Resource Center) were immersed in TBS (20 mM Tris, pH 7.4, and
8.75% NaCl), rinsed three times with 10 mM phosphate buffer, and twice
with diluting buffer (10 mM phosphate containing 2% BSA, 0.4% Triton
X-100, and 1% normal goat serum). The tissue sections were incubated in
20% normal goat serum in 10 mM phosphate buffer for 10 min, after
which they were incubated with rabbit anti–APP-BP1, BP339, or with rab-
bit anti-NEDD8 at room temperature for 40 h. Sections were washed once
in 10 mM phosphate buffer and twice in diluting buffer. The sections were
incubated with Alexa Fluor goat anti–rabbit overnight and washed before
they were mounted onto slides.
Confocal images in Fig. 2 (B and C), Fig. 3 D, and Fig. 4 were all col-
lected with the confocal system (model TCS SP2; Leica) using the confocal
software (LCS; Leica; 40
 
 
 
; NA 1.25; zoom 1
 
 
 
). In Fig. 3 D, APP-BP1 im-
munofluorescence was visualized by confocal microscopy, using the same
settings for each case. In Fig. 4 B, images were collected in three channels.
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